Eli Lilly Announces Results From Two Multi-Year Phase 3 Studies Showing Patients Treated With Mirikizumab, Sustained Stable, Long-Term Remission Across Ulcerative Colitis And Crohn's Disease; At Three Years, Over 80% Of Patients With Moderately To Severely Active UC Who Were In Remission With Mirikizumab Sustained Long-term Remission And Relief From Disruptive Symptoms
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly announced positive results from two multi-year Phase 3 studies showing that patients treated with Mirikizumab sustained long-term remission in ulcerative colitis and Crohn's disease. Over 80% of patients with moderately to severely active ulcerative colitis who were in remission with Mirikizumab maintained long-term remission and relief from symptoms.
October 28, 2024 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Mirikizumab demonstrated strong results in Phase 3 studies, with over 80% of ulcerative colitis patients maintaining long-term remission. This could positively impact LLY's stock price.
The positive results from the Phase 3 studies of Mirikizumab suggest a strong potential for Eli Lilly in the treatment of ulcerative colitis and Crohn's disease. This could lead to increased investor confidence and a potential rise in LLY's stock price.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90